000 | 01958 a2200577 4500 | ||
---|---|---|---|
005 | 20250513183525.0 | ||
264 | 0 | _c19990610 | |
008 | 199906s 0 0 eng d | ||
022 | _a0022-2623 | ||
024 | 7 |
_a10.1021/jm980702n _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aMoreau, P | |
245 | 0 | 0 |
_aSynthesis, mode of action, and biological activities of rebeccamycin bromo derivatives. _h[electronic resource] |
260 |
_bJournal of medicinal chemistry _cMay 1999 |
||
300 |
_a1816-22 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAminoglycosides |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAnti-Bacterial Agents _xchemical synthesis |
650 | 0 | 4 |
_aAnti-HIV Agents _xchemical synthesis |
650 | 0 | 4 |
_aAntineoplastic Agents _xchemical synthesis |
650 | 0 | 4 |
_aBacillus cereus _xdrug effects |
650 | 0 | 4 |
_aCarbazoles _xchemical synthesis |
650 | 0 | 4 | _aCattle |
650 | 0 | 4 |
_aDNA _xchemistry |
650 | 0 | 4 |
_aDNA Topoisomerases, Type I _xchemistry |
650 | 0 | 4 |
_aEnzyme Inhibitors _xchemical synthesis |
650 | 0 | 4 |
_aGlucose _xanalogs & derivatives |
650 | 0 | 4 | _aIndoles |
650 | 0 | 4 | _aInhibitory Concentration 50 |
650 | 0 | 4 |
_aPhosphotransferases _xantagonists & inhibitors |
650 | 0 | 4 |
_aProtein Kinase C _xantagonists & inhibitors |
650 | 0 | 4 | _aStructure-Activity Relationship |
650 | 0 | 4 | _aTopoisomerase I Inhibitors |
650 | 0 | 4 | _aTumor Cells, Cultured |
700 | 1 | _aAnizon, F | |
700 | 1 | _aSancelme, M | |
700 | 1 | _aPrudhomme, M | |
700 | 1 | _aSevère, D | |
700 | 1 | _aRiou, J F | |
700 | 1 | _aGoossens, J F | |
700 | 1 | _aHénichart, J P | |
700 | 1 | _aBailly, C | |
700 | 1 | _aLabourier, E | |
700 | 1 | _aTazzi, J | |
700 | 1 | _aFabbro, D | |
700 | 1 | _aMeyer, T | |
700 | 1 | _aAubertin, A M | |
773 | 0 |
_tJournal of medicinal chemistry _gvol. 42 _gno. 10 _gp. 1816-22 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1021/jm980702n _zAvailable from publisher's website |
999 |
_c10305615 _d10305615 |